Cargando…
Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
BACKGROUND: This is a dosimetric comparative study intended to establish appropriate low-to-intermediate dose-constraints for the rectal wall (R(wall)) in the context of a randomized phase-II trial on urethra-sparing stereotactic body radiotherapy (SBRT) for prostate cancer. The effect of plan optim...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008922/ https://www.ncbi.nlm.nih.gov/pubmed/29921291 http://dx.doi.org/10.1186/s13014-018-1059-1 |
_version_ | 1783333278367875072 |
---|---|
author | Dubouloz, Angèle Rouzaud, Michel Tsvang, Lev Verbakel, Wilko Björkqvist, Mikko Linthout, Nadine Lencart, Joana Pérez-Moreno, Juan María Ozen, Zeynep Escude, Lluís Zilli, Thomas Miralbell, Raymond |
author_facet | Dubouloz, Angèle Rouzaud, Michel Tsvang, Lev Verbakel, Wilko Björkqvist, Mikko Linthout, Nadine Lencart, Joana Pérez-Moreno, Juan María Ozen, Zeynep Escude, Lluís Zilli, Thomas Miralbell, Raymond |
author_sort | Dubouloz, Angèle |
collection | PubMed |
description | BACKGROUND: This is a dosimetric comparative study intended to establish appropriate low-to-intermediate dose-constraints for the rectal wall (R(wall)) in the context of a randomized phase-II trial on urethra-sparing stereotactic body radiotherapy (SBRT) for prostate cancer. The effect of plan optimization on low-to-intermediate R(wall) dose and the potential benefit of an endorectal balloon (ERB) are investigated. METHODS: Ten prostate cancer patients, simulated with and without an ERB, were planned to receive 36.25Gy (7.25Gyx5) to the planning treatment volume (PTV) and 32.5Gy to the urethral planning risk volume (uPRV). Reference plans with and without the ERB, optimized with respect to PTV and uPRV coverage objectives and the organs at risk dose constraints, were further optimized using a standardized stepwise approach to push down dose constraints to the R(wall) in the low to intermediate range in five sequential steps to obtain paired plans with and without ERB (Vm(1) to Vm(5)). Homogeneity index for the PTV and the uPRV, and the Dice similarity coefficient (DSC) for the PTV were analyzed. Dosimetric parameters for R(wall) including the median dose and the dose received by 10 to 60% of the R(wall), bladder wall (B(wall)) and femoral heads (F(Heads)) were compared. The monitor units (MU) per plan were recorded. RESULTS: Vm(4) reduced by half D(30%), D(40%), D(50%,) and D(med) for R(wall) and decreased by a third D(60%) while HI(PTV), HI(uPRV) and DSC remained stable with and without ERB compared to Vm(ref). HI(PTV) worsened at Vm(5) both with and without ERB. No statistical differences were observed between paired plans on R(wall), B(wall) except a higher D(2%) for F(heads) with and without an ERB. CONCLUSIONS: Further optimization to the R(wall) in the context of urethra sparing prostate SBRT is feasible without compromising the dose homogeneity to the target. Independent of the use or not of an ERB, low-to-intermediate doses to the R(wall) can be significantly reduced using a four-step sequential optimization approach. |
format | Online Article Text |
id | pubmed-6008922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60089222018-06-26 Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? Dubouloz, Angèle Rouzaud, Michel Tsvang, Lev Verbakel, Wilko Björkqvist, Mikko Linthout, Nadine Lencart, Joana Pérez-Moreno, Juan María Ozen, Zeynep Escude, Lluís Zilli, Thomas Miralbell, Raymond Radiat Oncol Research BACKGROUND: This is a dosimetric comparative study intended to establish appropriate low-to-intermediate dose-constraints for the rectal wall (R(wall)) in the context of a randomized phase-II trial on urethra-sparing stereotactic body radiotherapy (SBRT) for prostate cancer. The effect of plan optimization on low-to-intermediate R(wall) dose and the potential benefit of an endorectal balloon (ERB) are investigated. METHODS: Ten prostate cancer patients, simulated with and without an ERB, were planned to receive 36.25Gy (7.25Gyx5) to the planning treatment volume (PTV) and 32.5Gy to the urethral planning risk volume (uPRV). Reference plans with and without the ERB, optimized with respect to PTV and uPRV coverage objectives and the organs at risk dose constraints, were further optimized using a standardized stepwise approach to push down dose constraints to the R(wall) in the low to intermediate range in five sequential steps to obtain paired plans with and without ERB (Vm(1) to Vm(5)). Homogeneity index for the PTV and the uPRV, and the Dice similarity coefficient (DSC) for the PTV were analyzed. Dosimetric parameters for R(wall) including the median dose and the dose received by 10 to 60% of the R(wall), bladder wall (B(wall)) and femoral heads (F(Heads)) were compared. The monitor units (MU) per plan were recorded. RESULTS: Vm(4) reduced by half D(30%), D(40%), D(50%,) and D(med) for R(wall) and decreased by a third D(60%) while HI(PTV), HI(uPRV) and DSC remained stable with and without ERB compared to Vm(ref). HI(PTV) worsened at Vm(5) both with and without ERB. No statistical differences were observed between paired plans on R(wall), B(wall) except a higher D(2%) for F(heads) with and without an ERB. CONCLUSIONS: Further optimization to the R(wall) in the context of urethra sparing prostate SBRT is feasible without compromising the dose homogeneity to the target. Independent of the use or not of an ERB, low-to-intermediate doses to the R(wall) can be significantly reduced using a four-step sequential optimization approach. BioMed Central 2018-06-19 /pmc/articles/PMC6008922/ /pubmed/29921291 http://dx.doi.org/10.1186/s13014-018-1059-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Dubouloz, Angèle Rouzaud, Michel Tsvang, Lev Verbakel, Wilko Björkqvist, Mikko Linthout, Nadine Lencart, Joana Pérez-Moreno, Juan María Ozen, Zeynep Escude, Lluís Zilli, Thomas Miralbell, Raymond Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? |
title | Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? |
title_full | Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? |
title_fullStr | Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? |
title_full_unstemmed | Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? |
title_short | Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? |
title_sort | urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008922/ https://www.ncbi.nlm.nih.gov/pubmed/29921291 http://dx.doi.org/10.1186/s13014-018-1059-1 |
work_keys_str_mv | AT duboulozangele urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT rouzaudmichel urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT tsvanglev urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT verbakelwilko urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT bjorkqvistmikko urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT linthoutnadine urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT lencartjoana urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT perezmorenojuanmaria urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT ozenzeynep urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT escudelluis urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT zillithomas urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon AT miralbellraymond urethrasparingstereotacticbodyradiotherapyforprostatecancerhowmuchcantherectalwalldosebereducedwithorwithoutanendorectalballoon |